On April 30, 2025, ABVC BioPharma, Inc. reported that it was notified by Nasdaq about failing to meet stockholders' equity requirements, with only $723,959 as of April 23, 2025, and must submit a compliance plan by June 8, 2025. Additionally, the company sold 724,372 shares for over $436,000 to non-U.S. investors under Regulation S, granting voting rights to its chairman.